Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2012-12-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk subjects for psychosis?
* What about the dopamine synthesis in recurred clinical high risk subjects for psychosis after the discontinuation?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia
NCT02248987
Predicting Antipsychotic Discontinuation in Psychosis
NCT02884518
Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation
NCT05667961
Antipsychotic Induced Structural and Functional Brain Changes
NCT02435095
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
NCT01160679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Controls
Healthy control
No interventions assigned to this group
patients
clinical high risk subjects for psychosis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treated with antipsychotic drugs
* PSP1-5 (from SIPS criteria) \<3 (severity index)for more than 6 months
* Had not experienced a symptomatic relapse in the 6 months
Exclusion Criteria
* History of head trauma
16 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jun Soo Kwon
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Soo Kwon, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-1207-055-417
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.